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Abstract 
Carcinomatous meningitis due to bladder cancer is a rare entity reported only in case 
reports. Optimal therapy is thus poorly defined with earlier cases reporting an 
unsuccessful outcome. Here we report a case of late carcinomatous meningitis secondary 
to transitional cell carcinoma (TCC) of the bladder occurring in a patient in complete 
remission. He was successfully treated with intrathecal methotrexate and whole brain 
irradiation and experienced prolonged survival after treatment. With modern 
chemotherapy increasing complete remissions and survival rates in patients with TCC, 
more and more patients are being reported with carcinomatous meningitis. We raise the 
question of whether central nervous system prophylaxis should be considered in 
patients with TCC achieving a complete remission to chemotherapy in the metastatic 
setting. 
 
Introduction 
Carcinomatous meningitis due to bladder cancer is a rare entity reported only in case 
reports. Optimal therapy is thus poorly defined, with most cases reporting an 
unsuccessful outcome. Here, we report a case of carcinomatous meningitis secondary to 
transitional cell carcinoma (TCC) of the bladder successfully treated with intrathecal 
methotrexate (MTX) and whole brain irradiation. Case Rep Oncol 2011;4:406–412 
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Case Report 
A 47-year-old white male presented with TCC of the bladder which had metastasized to bone as 
revealed by PET-CT. Chemotherapy with cisplatin and gemcitabine resulted in a radiographic complete 
remission after 7 cycles. Three months after completing chemotherapy, the patient presented with 
headache. A brain MRI suggested carcinomatous meningitis (see fig. 1, fig. 2). He then developed a 
right CN III palsy. A lumbar puncture confirmed the diagnosis (see fig. 3). The patient was treated with 
biweekly intrathecal MTX via an Ommaya reservoir for 6 weeks, resulting in the clearance of his 
cerebrospinal fluid; however, his cranial nerve palsy persisted. He then underwent whole brain 
irradiation (3,960 cGy at 180 cGy per day over 22 days by the ‘German Helmet’ technique) with 
resolution of his cranial nerve palsy. He is currently alive 9 months after his diagnosis of carcinomatous 
meningitis. 
Discussion 
Cancer of the urinary bladder is diagnosed in approximately 70,500 people each year in 
the United States, and about 14,000 individuals die [1]. Central nervous system (CNS) 
involvement is rarely reported. In a study by Anderson et al. [2] involving CNS 
complications occurring in bladder cancer, no patient developed carcinomatous 
meningitis and only 1% of patients developed brain metastasis in a series of 359 patients. 
For carcinomatous meningitis associated with other solid tumors, a typical induction 
regimen consists of a fixed dose of 10 or 12 mg of intrathecal MTX twice weekly for 4 
weeks. If clinical response occurs, the frequency of administration is decreased to once 
weekly for 4–8 weeks; a maintenance regimen is then continued with drug administration 
every 2 weeks for several months, and then monthly for 2–4 months. The optimal 
duration of therapy is unknown [3]. 
The route of delivery of intrathecal chemotherapy may impact outcome. Shapiro et al. 
[4] demonstrated that MTX administration using an Ommaya reservoir more reliably 
produced adequate cerebrospinal fluid distribution than administration by lumbar 
puncture. In another study, 100 patients with clinically and cytologically or 
radiographically documented neoplastic meningitis stemming from solid tumors received 
intracerebrospinal fluid liposomal cytarabine or MTX. Progression-free survival (the 
primary study endpoint) was identical between the sustained-release cytarabine and MTX 
treatment arms for all 100 patients (35 vs. 37.5 days, respectively, p = 0.79). When 
progression-free survival was examined as a function of the route of chemotherapy 
administration (lumbar vs. ventricular), there was no difference for patients treated with 
sustained-release cytarabine (29 vs. 43 days, respectively, p = 0.35). For patients treated 
with MTX, however, there was a statistically significant difference favoring patients 
receiving intraventricular therapy (19 vs. 43 days, respectively, p = 0.048) [5]. Hitchins et 
al. [6] also noted that responses were more frequent if therapy was administered via an 
Ommaya reservoir. We speculate that placing an Ommaya reservoir in our patient may 
have contributed to his relatively prolonged overall survival.  
There are several cases of transitional cell carcinomatous meningitis reported in the 
literature – with our case bringing the total to 30. While some patients presented with 
grossly widespread disease including the CNS, our literature review suggests that many 
patients had the complication occur after successful treatment of their systemic disease 
(see table 1). For example, Bishop et al. [7] reported 2 patients developing disease after 
systemic treatment with MTX, vinblastine, Adriamycin, and cisplatin (MVAC). Case Rep Oncol 2011;4:406–412 
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Matsushita et al. [8] reported a case occurring 16 months after their patient had had a 
complete response following chemotherapy and surgery, and Boukriche et al. [9] reported 
a case occurring 4 years after adjuvant treatment for resected bladder cancer. Still, just as 
many cases present concurrently with widespread systemic disease, suggesting that TCC 
may have an affinity for the CNS and that carcinomatous meningitis may be more 
common than realized. The prognosis for most patients with carcinomatous meningitis 
secondary to TCC is dismal, with patients surviving a median of 38 days [31]. Our review 
confirms the poor prognosis with an average survival of 2.2 months for all patients in 
which survival has been reported. Interestingly, the average time to the development of 
carcinomatous meningitis is 14 months (see table 1). 
With more cases appearing in the literature, it raises the question: does the successful 
treatment of systemic disease with modern chemotherapy change the natural history of 
the disease? Dhote et al. [33] reported on 50 patients with advanced TCC of the bladder 
treated with MVAC and noted that 8 patients experienced a CNS relapse (16%). In their 
series, brain metastasis occurred within a mean of 21 months. In the series by Bishop et al. 
[6], 2 of 17 patients treated with MVAC had carcinomatous meningitis (12%). Finally, in 
a series reported by Sternberg et al. [34], 2 out of 12 patients achieving complete response 
on MVAC later developed CNS disease (17%). We can only surmise that in the series by 
Anderson et al. [2], in which data was collected on patients between 1962 and 2001, the 
majority of patients did not receive cisplatin-based chemotherapy. With the rising 
incidence of TCC of the bladder, more and more patients are now dying of complications 
seen only in advanced stages of disease. With modern chemotherapy, median survival has 
increased from 3–6 months in the pre-MVAC era to its current figure of almost 1 year. 
This combination chemotherapy, in a multicenter phase III trial, was shown to increase 
median survival from 8.2 to 12.5 months [35]. As with any chemotherapy, MVAC is 
associated with complications like cardiac and renal toxicities, along with neutropenia 
and mucositis. The rate of death due to MVAC toxicity is around 3–4% and the disease-
free survival rate is 3.7% at 6 years [34, 35]. A newer phase III study has shown the clear 
advantage of using the gemcitabine-cisplatin combination as it is as effective as MVAC, 
but with less systemic toxicity [36]. Reports of carcinomatous meningitis occurring when 
the gemcitabine-cisplatin combination is used are increasing, similar to the trend 
reported for MVAC. As more and more cases appear in the literature, it may be 
reasonable to consider CNS prophylaxis in patients who achieve complete remission on 
chemotherapy in a metastatic setting. 
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Table 1. Summary of reported cases on transitional cell carcinoma of bladder and its metastasis to CNS 
Study 
first author 
Stage  
at DX 
Disease course and treatment summary     CR  Time to  
CNS disease 
months 
TX CNS  OS after 
CNS disease 
months 
Hust, 1980 [10]  nr  cobalt XRT     nr  5  none  5 
Hust, 1980 [10]  IV   meningitis at presentation    na  0  none  0 
Mandell, 1985 [11]  nr  radiation and cystectomy at diagnosis, cisplatin × 5 
at relapse 
 yes  10  IT  MTX/XRT  nr 
Bishop, 1990 [7]  III  MVAC × 4, meningitis after cycle 4    no  32  IT MTX/XRT  5 
Bishop, 1990 [7]  T4  cystectomy, MVAC × 3, meningitis after cycle 3     no  –  none  4 
Hussien, 1989 [12]  IV  MVAC × 5, PR, progressed in 3 months, phase I 
piritrexim with PR  
 no  9  IT  MTX/XRT  5 
Raghavan, 1991 [13]  nr  cisplatin and radiation for localized disease relapsed in 
16 months, MVAC × 2, IT therapy and 
MVAC × 4 
 yes  16  IT  MTX-O  4 
Eng, 1993 [14]  IV   MVAC × 5, pelvic XRT, PR     no  9  none  0 
Eng, 1993 [14]  IV   cisplatin and MTX with CR, relapsed 2 years later    yes  24  IT MTX/XRT  3 
Steg, 1993 [15]  nr  nr    nr  nr  none  1 
Sugimori, 2005 [16]  IV  presented with meningitis, died of cardiac disease    na  0  none  3 
Imamura, 1997 [17]  IV  presented with meningitis    na  0  none  3 
Bloch, 1987 [18]  IV   surgery for presumed localized disease, brain 
metastasis 2 weeks after surgery, whole body XRT, 
meningitis 3 months later 
 na  3  –  5 
Hasbini, 1997 [19]  T3N2  surgery, MVAC × 4 with CR, meningitis  
1 month later  
 yes  7  –  1 
Santarossa, 1997 [20]  T4N3  MVAC × 6, presented 8 months later with meningitis    yes  14  IT MTX/XRT  9 
Loizaga, 1998 [21]  I  BCG vaccine, mitomycin B, then developed  
meningitis 
 na  15  CMV  0 
Cozzarini, 1999 [22]  III  MVAC × 2 with no improvement, surgery, 
MVAC × 4, then developed meningitis 
 no  6  IT  MTX  3 
Cozzarini, 1999 [22]  III  MVAC × 3, PR, surgery, MVAC × 2    no  9  IT MTX  1 
Vidal, 2000 [23]  IV  presented with carcinomatous meningitis, 
4 doses IT MTX.  
 na  0  IT  MTX  1 
Vidal, 2000 [23]  IV   presented with panhypopituitarism, later diagnosed 
with meningitis 
 na  1  none  2 
Bruna, 2001 [24]  IV  presented with meningitis, died of infection    na  0  IT MTX  2 
Bodi, 2004 [25]  I  TURBT    na  9  none  1.5 
Matsushita, 2004 [26]  III  MVAC × 3, surgery    yes  16  none  25 
Kim, 2005 [27]  nr  surgery    na  108  none  1 
Goodman, 2009 [28]  IV  taxol/carboplatin/gemcitabine/trastuzumab, surgery    yes  nr  IT MTX-O   1.5 
Butchart, 2010 [29]  II  gemcitabine-cisplatin, XRT    yes  5  none  1 
Bowen, 2010 [30]  nr  surgery, gemcitabine-cisplatin × 4    yes  31  XRT  nr 
Uncu, 2010 [31]  IV  radiation, gemcitabine-cisplatin × 6, relapsed in  
lungs in 22 months, gemcitabine-cisplatin resumed, 
CNS disease 2 months later 
 yes  36  IT  MTX/XRT  2 
Zada, 2010 [32]  IV  nr    nr  nr  nr  nr 
Tadepalli, 2010 [current 
report] 
 
IV 
 
MVAC × 7  
  
yes 
 
14 
 
IT MTX/XRT 
 
8 
CR = Complete remission; Dx = diagnosis; IT = intrathecal; MTX = methotrexate; MVAC = methotrexate, vinblastine, doxorubicin, and cisplatin;
na = not applicable; nr = not reported; OS = overall survival; PR = partial remission; TURBT = transurethral resection of bladder tumor; Tx = 
treatment; XRT = radiation. 
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Fig. 1. T1-weighted gadolinium-enhanced MRI showing abnormal leptomeningeal enhancement 
patterns of the infratentorial compartment and the supratentorial basal cisterns. 
 
 
 
Fig. 2. T1-weighted gadolinium-enhanced MRI showing left cerebellar encephalomalacia consistent 
with an old infarct of the left posterior inferior cerebellar artery. 
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Fig. 3. Cytospin analysis of cerebrospinal fluid reveals numerous malignant cells with features 
consistent with metastatic high-grade TCC including large, atypical cells with increased nuclear size, 
prominent nucleoli, and irregular nuclear contours (a–c). Clusters of atypical cells with a papillary 
configuration are also identified (d). (HE ×400). 
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